&
PHARMACO GENOMICS
What is Pharmacogenomics ?
The MyNicas Opportunity
Protocol for Genetic Testing in Cardiac and
Hypertension Drug Administration:
Adjunct diagnosis for MyNicas
MyNicas identifies physiologic issue
HCP determines Drug Category and Class
PGx Testing guides final choice of drug
MyNicas will provide a critical component for any Pharmacogenetic company wishing to validate and document the success of recommended hypertension and / or cardiac medications prescribed based on their testing..
YOU CAN’T PROVE THE EFFECTIVENESS OF MEDICATION PROTOCOLS… IF YOU CAN’T MEASURE THEM…
MyNicas Validation through Navigation
​
Please contact Tom Jordan at tjordanrcr@yahoo.com for more details.
Pharmacogenomics is the study of how genes affect a person’s response to drug therapy.
​
The importance of Appropriate Medication Selection can be measured as follows:
​
• $177 Billion Spent on Adverse Drug Reactions annually
• Two times increase in Length of Stay hospitalizations for patients with Adverse Drug Reactions
• 6.7% of hospitalized patients have a serious Adverse drug Reaction
How can Pharmacogenomics Testing Help ?
FDA Approved medications are based on averages in large clinical trials and individualized responses cannot always be predicted.
Rationale: Pharmacogenomics can help predict how a patient will respond to a cardiac or hypertension drug based on the patients’ individual genetic makeup and phenotype related to drug absorption, metabolism and activity.
Pharmacogenetic test can provide valuable information allowing the physician to provide “Targeted Medication Management” which categorizes drug recommendations specific to a patient’s diagnosis and current medications in four quadrants